Microcap Ledger Editas Medicine, Inc. $EDIT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Cambridge, MA
- Fiscal year end
- December 31
- Shares outstanding
- 153,580,035 [10-Q 2026-08-05]
What the company doesAI summary of filing
Editas Medicine is a preclinical-stage gene editing company that develops CRISPR-based genomic medicines to treat serious diseases. The company has not generated revenue from product sales and is focused on in vivo gene editing programs, with its lead candidate EDIT-401 in preclinical development for treating high cholesterol by upregulating the LDL receptor gene. Editas makes money through licensing its CRISPR technology to partners such as Vertex Pharmaceuticals and Bristol Myers Squibb, receiving upfront payments, milestone payments, and royalties on future sales. The company operates a proprietary gene editing platform based on CRISPR/Cas9 and CRISPR/Cas12a enzymes and pursues both internal development and in-licensing of complementary technologies to advance its pipeline. [10-K 2026-03-09]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $14.72M | −$43.21M | −$52.63M | $181.81M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | $40.52M | −$160.06M | −$165.24M | $146.65M | [10-K 2026-03-09] |
| FY ended Dec 2024 | $32.31M | −$237.09M | −$210.28M | $131.54M | [10-K 2026-03-09] |
- Quarterly cash burn
- −$26.31M
- Cash runway Estimate
- ~20.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-30 | 82,548,099 | [10-Q 2024-11-04] |
| 2025-02-28 | 82,976,284 | [10-K 2025-03-05] |
| 2025-05-07 | 83,712,859 | [10-Q 2025-05-12] |
| 2025-08-07 | 89,920,164 | [10-Q 2025-08-12] |
| 2025-10-31 | 97,618,660 | [10-Q 2025-11-10] |
| 2026-02-27 | 97,871,999 | [10-K 2026-03-09] |
| 2026-04-29 | 97,906,282 | [10-Q 2026-05-05] |
| 2026-07-31 | 153,580,035 | [10-Q 2026-08-05] |
- Shelf registration
- S-3 filed 2026-08-31; declared effective 2026-09-08 [S-3 2026-08-31]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-03 | Burkly Linda | sell | 709 | $3.04 | [4 2026-09-04] |
| 2026-09-03 | Parison Amy | sell | 453 | $3.04 | [4 2026-09-04] |
| 2026-09-03 | O'Neill Gilmore Neil | sell | 5,124 | $3.04 | [4 2026-09-04] |
| 2026-08-03 | Parison Amy | sell | 678 | $2.58 | [4 2026-08-05] |
| 2026-07-28 | Burkly Linda | sell | 4,928 | $2.67 | [4 2026-07-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-08 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-31 | S-3 | Registration statement |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations; Director or officer change |
| 2026-07-29 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-18 | 8-K | Shareholder vote results |
| 2026-06-03 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-03 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-02 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-26 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-26 | 8-K | Material agreement entered; Other events |
Alerts for $EDIT
Email me when Editas Medicine, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.